BioSpectrum Asia

Singapore approves GSK’s new ovarian cancer therapy


GlaxoSmith­Kline (GSK) Singapore has announced that Health Sciences Authority has approved Zejula (niraparib) tablet, an oral, once-daily first-line and recurrent maintenanc­e treatment for women with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following platinum-based chemothera­py. This new product registrati­on makes Zejula the only poly (ADP-ribose) polymerase (PARP) inhibitor approved in Singapore for use as a monotherap­y for patients with advanced and recurrent ovarian cancer, regardless of whether they have a BRCA mutation. Zejula is available for first-line ovarian cancer (PRIMA) in 44 countries and 2 Special Administra­tive Regions as of March 2022. Zejula is also being assessed across multiple tumour types and evaluated in combinatio­ns with several other therapeuti­cs. Notably, it is currently being tested in a Phase III clinical trial, ZEST, exploring its further potential in treating patients with triple-negative breast cancer (TNBC) or BRCAm HER2- breast cancer, mutations which require specialise­d treatment.

 ?? ??

Newspapers in English

Newspapers from India